Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 May:81:100898.
doi: 10.1016/j.resmer.2022.100898. Epub 2022 May 5.

Updated guidelines (2021) for management and follow-up of asthmatic patients of the French Society of Pneumology (SPLF) and the French Society of Pediatric Pneumology and Allergology (SP2A). Short version

Chantal Raherison-Semjen  1 , Laurent Guilleminault  2 , Isabelle Billiart  3 , Cécile Chenivesse  4 , Annie De Oliveira  5 , Armine Izadifar  6 , Alain Lorenzo  5 , Cécilia Nocent  7 , Jean-Philippe Oster  8 , Mireille Padovani  9 , Thierry Perez  10 , Maud Russier  11 , Magali Steinecker  5 , Alain Didier  12
Affiliations
Practice Guideline

Updated guidelines (2021) for management and follow-up of asthmatic patients of the French Society of Pneumology (SPLF) and the French Society of Pediatric Pneumology and Allergology (SP2A). Short version

Chantal Raherison-Semjen et al. Respir Med Res. 2022 May.

Abstract

The therapeutic management strategy is based on the regular evaluation of the control of asthmatic disease, with an effective minimum dose research and the assessment of environmental factors, not to mention the important place of therapeutic education. These professional recommendations relate to the management and follow-up of adult and adolescent asthma patients aged 12 and over. The recommendations answer the following questions: 1. How to make the initial diagnosis of asthma? 2. What allergological check-up should be done in asthmatics 3. How to manage an asthma exacerbation? 4. How to manage difficult asthma? 5. What therapeutic strategies? 6. How to manage a woman's asthma during pregnancy? 7. Environmental factors in asthma management review.

Keywords: Allergy; Asthma; Management; Pregnancy; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Over the last 5 years, M. Russier has received fees or funding for participation in conferences, communications, training activities, participation in expert panels from Astra Zeneca, Chiesi, Novartis and Sanofi. Over the last 5 years, M. Russier was principal investigator of clinical studies sponsored by AstraZeneca. Over the last 5 years, A. Lorenzo has received the following from Novartis: ERS congress invitation. Over the last 5 years, C. RAHERISON SEMJEN has received fees or funding for participation in conferences, communications, training activities, counselling, participation in expert panels, research activities from ALK, Astra Zeneca, Boeringher Ingelheim, Chiesi, GSK, Novartis and Sanofi. Over the last 5 years, L. Guilleminault has received fees or funding for participation in conferences, communications, training activities, research activities, participation in expert panels, writing of articles or documents, counselling and expertises from ALK, AstraZeneca, Bayer, Chiesi, GlaxoSmithKline, MSD, Novartis, Sanofi and Stallergènes. Over the last 5 years, I. BILLIART has received fees or funding for participation in training activities and expert panels from Novartis, GSK and AstraZeneca. Over the last 5 years, Cécile Chenivesse has received fees or funding from ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKlein, Nouveau Souffle, Novartis, Sanofi-Regeneron, Pierre Fabre, Pfizer, Roche, Santelys and TEVA Over the last 5 years, C. Nocent-Ejnain has received fees or funding for participation in conferences, communications, training activities, counselling, participation in expert panels from GSK, AstraZeneca, Novartis, ALK, Mundipharma, Chiesi, Menhari, Sanofi, Isis Medical and sos oxygene. Over the last 5 years, A. DIDIER has received fees or funding for participation in conferences, participation in expert panels, counselling and expertise missions from AstraZeneca, GSK, Chiesi, Stallergènes, ALK, Novartis, Boehringer Ingelheim, BMS, Menarini, Sanofi and Zambon. The other authors state that they have no links of interest. The document was reviewed by the Scientific Council of the SPLF (B. Maitre, C. Leroyer) and the members of the review group: B. Stach, P. Bonniaud, D. Holtea, L. Portel.

Publication types